Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01892488 |
Recruitment Status :
Completed
First Posted : July 4, 2013
Last Update Posted : June 5, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) | Drug: Sultamicillin Drug: Placebo | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 295 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study |
Actual Study Start Date : | June 7, 2013 |
Actual Primary Completion Date : | April 23, 2019 |
Actual Study Completion Date : | June 5, 2019 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: lactose pill
Placebo for 5 days as supplement to standard of care for patients with AE-COPD
|
Drug: Placebo
Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated. Control intervention: Placebo for 5 days as supplement to standard of care for patients with AE-COPD Other Name: Placebo: Lactose pill |
Experimental: Sultamicillin
Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
|
Drug: Sultamicillin
Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated. Experimental intervention: Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD. Other Name: aminopenicillin + betalactamase inhibitor |
- Additional antibiotic therapy to study medication during treatment period or until the test of cure visit (at day 30) [ Time Frame: up to day 30 ]
Assessment of additional antibiotic therapy:
Patients will be asked at every visit about use of additional antibiotic therapy. In the case of use of additional antibiotic therapy the exact starting date, the active compound, the dose administered, the route of administration,the length of treatment and the indication will be registered. Only additional antibiotic therapy for AE-COPD will be counted as treatment failure.
- To evaluate long-term consequences of Placebo treatment [ Time Frame: up to 1 year ]
- Relapse rate
- Time to relapse
- To assess patient's clinical improvement relative to treatment [ Time Frame: up to 30 days ]
- Clinical cure rate at the "end of therapy visit" (at day 6)
- Clinical cure rate at the "test Of cure visit" (at day 30) (both determined by patient-centered outcomes (diary cards))
- To assess additional efficacy endpoints and health outcome evaluations [ Time Frame: up to 1 year ]
- Changes in COPD Assessment Test(CAT)
- Changes in Exacerbations of Chronic Pulmonary Disease Tool-Patient reported outcome (EXACT-PRO)
- Additional antibiotic therapy
- Time to next exacerbation
- Number of exacerbations during follow up
- Per-subject relapse rate at the LFU (Late Follow Up) visits in the subset of subjects in the CE population who were clinically cured at the TOC visit
- Changes in length of stay in hospital for hospitalized patients
- All cause mortality
- Assessment of safety: [ Time Frame: up to 1 year ]
Key criteria for safety are:
adverse events, serious adverse events, changes in physical examination, vital signs, laboratory tests

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adults, either sex, older or equal than 40 years of age
-
For female patients, the following conditions are to be met:
- has been postmenopausal for at least 1 year, or
- is surgically incapable of bearing children, or
-
is of childbearing potential, and the following conditions are met:
- has a negative pregnancy test (urine- or serum-based) immediately before study entry (i.e., before the start of treatment or any other study procedure that could potentially harm the fetus), and one or more of following criteria
- must agree to abstinence or use an accepted method of contraception. The subject must agree to continue with the same method throughout the study.
- having only female sexual partners
- sexual relationship with sterile male partners only
- Patients diagnosed with COPD stages I-IV as defined by the Global initiative for chronic Obstructive Lung disease (GOLD).
and
- Doctor's diagnosis of acute (onset < 7 days) moderate exacerbation of COPD defined by a sustained worsening of the patient's condition (including at least 2 of the following symptoms: increased dyspnea, increased sputum production, sputum purulence and increased cough), from the stable state and beyond normal day-to-day variations, necessitating a change in regular medication in patient with underlying COPD, needing additional medical assistance.
- Absence of community acquired pneumonia or lower respiratory tract infection with a clear indication for antibiotic treatment as determined by Procalcitonin level < 0.25 ng/mL and/or absence of pulmonary infiltrates on routine chest x-ray.
- Smoking history of at least 10 Pack Years or more.
- Patients must be able to complete diaries and quality of life questionnaires.
- Patients must sign and date an informed consent prior to any study procedures.
Exclusion Criteria:
- Severe exacerbation: defined by need for ventilatory support (indicated by severe dyspnea with failure to respond to emergency treatment and/or persistent hypoxemia (PaO2 <50 mm Hg despite O2 administration and / or respiratory acidosis (pH <7.35 and PaCO2> 45mmHg)) or mental confusion or circulatory insufficiency (need of vasopressors)
- Fever (>38.5°C)
- Known impaired hepatic or renal function
- Active or suspected tuberculosis infection of the respiratory tract
- Acute exacerbation of asthma
- Suspected or known hypersensitivity to, or suspected serious adverse reaction to sultamicillin; suspected or known hypersensitivity to penicillins or cephalosporins
- Immunosuppression or Immunosuppressive therapy (cytostatic chemotherapy within last 28 days or neutropenia (neutrophils < 1000/µ)l; systemic corticosteroids (≥20 mg prednisolon equivalent/day > 14 days; HIV-infection; immunosuppression after organ- or bone marrow transplant)- Patients with metastatic or hematological malignancy, splenectomized patients or patients with known hyposplenia or asplenia
- Oral/parenteral antibiotic use within 30 days prior to randomization (a singular administration of antibiotics prior to randomization is allowed)
- In-patient treatment within the last 30 days
- An antibiotic is clearly indicated for treatment of a known infection
- Known MRSA (methicillin-resistant Staphylococcus aureus) colonization or infection
- Patients with known bronchiectasis
- Patients with known bacterial airway colonization (>3 positive sputum cultures in the previous year)
- Progressively fatal disease, or life expectancy ≤6 months
- Mononucleosis
- Lymphatic leukemia
- Severe gastro-intestinal disorders with vomiting and diarrhea
- Women who are breast feeding
- Patients who have received treatment with any other investigational drug within 1 month prior to study entry, or have such treatment planned for the study period during treatment and follow up phase.
- Patients with mental conditions rendering them unable to understand the nature, scope, and possible consequences of the study.
- Patients unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow up visits, and unlikelihood of completing the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01892488

Study Director: | Gernot Rohde, Prof. Dr. | CAPNETZ Stiftung | |
Principal Investigator: | Tobias Welte, Prof.Dr. | Hannover Medical School |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Tobias Welte, Prof. Dr., Hannover Medical School |
ClinicalTrials.gov Identifier: | NCT01892488 |
Other Study ID Numbers: |
Protocol-Code: 002/2012 2012-003234-16 ( EudraCT Number ) |
First Posted: | July 4, 2013 Key Record Dates |
Last Update Posted: | June 5, 2020 |
Last Verified: | June 2020 |
COPD AE-COPD Chronic obstructive pulmonary disease acute exacerbations of Chronic obstructive pulmonary disease |
Pulmonary Disease, Chronic Obstructive Lung Diseases Lung Diseases, Obstructive Respiratory Tract Diseases Sultamicillin |
beta-Lactamase Inhibitors Anti-Bacterial Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |